COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL

被引：0
|
作者：
Pradelli, L. [1 ]
Iannazzo, S. [1 ]
Zaniolo, O. [1 ]
机构：
[1] AdRes Srl, Turin, Italy
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66370-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A403 / A404
页数：2
相关论文
共 50 条
  • [31] Effects of valsartan on left ventricular ejection fraction and diastolic diameter in patients with heart failure: Val-HeFT echocardiographic study
    Wong, M
    Staszewsky, L
    Latini, R
    Chiang, YT
    Volpi, A
    Hoglund, C
    Cohn, JN
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 141A - 141A
  • [32] Prognostic value of chronic obstructive pulmonary disease in heart failure patients: data from the Val-HeFT trial
    Staszewsky, L.
    Masson, S.
    Carretta, E.
    Amigoni, M.
    Wong, M.
    Anand, I.
    Cohn, J. N.
    Latini, R.
    EUROPEAN HEART JOURNAL, 2005, 26 : 280 - 280
  • [33] Stratification of baseline left ventricular dimension and ejection fraction determines response to valsartan in heart failure. Val-HeFT echocardiography study
    Wong, ML
    Staszewsky, L
    Anand, I
    Feliciano, N
    Hester, A
    Cohn, JN
    CIRCULATION, 2002, 106 (19) : 511 - 512
  • [34] Pre-trial severity of left ventricular dysfunction in heart failure determines outcomes: Val-HeFT echocardiography study
    Wong, M
    Barlera, S
    Staszewsky, L
    Baselier, MRP
    Naidoo, DP
    Souttern, S
    Aknay, N
    Anand, I
    EUROPEAN HEART JOURNAL, 2002, 23 : 450 - 450
  • [35] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (Val-HeFT).: N Engl J Med 2001;345:1667-1675 -: Comment -: Val-HeFT and angiotensin-receptor blockers in perspective:: A tale of the blind man and the elephant
    Cohn, JN
    Tognoni, G
    Konstam, MA
    JOURNAL OF CARDIAC FAILURE, 2002, 8 (02) : 56 - 58
  • [36] Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care - data from Val-HeFT
    Wong, Maylene
    Staszewsky, Lidia
    Carretta, Elisa
    Barlera, Simona
    Latini, Roberto
    Chiang, Yann-Tong
    Glazer, Robert D.
    Cohn, Jay N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (05) : 502 - 508
  • [37] Effect of valsartan on morbidity and mortality in patients with chronic heart failure receiving ACE inhibitors but not beta-blockers: Results from Val-HeFT
    Krum, H
    Farsang, C
    Maggioni, A
    CIRCULATION, 2002, 106 (19) : 511 - 511
  • [38] Prognostic value of the QRS duration in patients with heart failure: A subgroup analysis from 24 centers of Val-HeFT
    Hofmann, M
    Bauer, R
    Handrock, R
    Weidinger, G
    Goedel-Meinen, L
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (07) : 523 - 528
  • [39] COST-UTILITY ANALYSIS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE IN GREECE
    Stafylas, P.
    Farmakis, D.
    Kourlaba, G.
    Giamouzis, G.
    Chatzikou, M.
    Kossiva, E.
    Maniadakis, N.
    Parissis, J.
    VALUE IN HEALTH, 2016, 19 (07) : A654 - A654
  • [40] Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT
    Krum, Henry
    Latini, Roberto
    Maggioni, Aldo P.
    Anand, Inder
    Masson, Serge
    Carretta, Elisa
    Ingrilli, Franco
    Pettinati, Giacinto
    Glazer, Robert
    Tognoni, Gianni
    Cohn, Jay
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 119 (01) : 48 - 53
12345